The US and Canada have launched a joint investigation into the Titan sub implosion. This comes after the probe launch of the Omicron-specific mRNA-based booster vaccine, GEMCOVAC-OM, by Gennova Biopharmaceuticals. The vaccine received emergency use authorization from the Drug Controller General of India (DCGI) on June 20, 2023.
GEMCOVAC-OM is a thermostable vaccine, meaning it doesn’t require ultra-cold chain infrastructure for storage and transportation. This characteristic makes it easier to deploy in India, where cold chain infrastructure is not always available.
The vaccine’s primary purpose is to enhance the immune response against the Omicron variant of SARS-CoV-2. Clinical trials have demonstrated that GEMCOVAC-OM is safe, well-tolerated, and effectively stimulates an immune response against the Omicron variant.
Gennova Biopharmaceuticals is the current manufacturer of the vaccine. It is anticipated that the vaccine will be accessible in India within the next few weeks.
